tiprankstipranks
Abbvie (GB:0QCV)
NYSE:0QCV
UK Market
0QCV
AbbVie
RESEARCH TOOLSreports

AbbVie (0QCV) Share Forecast & Price Target

12 Followers
See the Price Targets and Ratings of:

0QCV Analyst Ratings

Moderate Buy
22Ratings
Moderate Buy
15 Buy
7 Hold
0 Sell
Based on 22 analysts giving stock ratings to
AbbVie
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0QCV Stock 12 Month Forecast

Average Price Target

$253.47
▲(19.75% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $253.47 with a high forecast of $299.00 and a low forecast of $223.00. The average price target represents a 19.75% change from the last price of $211.67.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"180":"$180","210":"$210","240":"$240","270":"$270","300":"$300"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":299,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$299.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":253.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$253.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":223,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$223.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[180,210,240,270,300],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,233.17,238.23384615384614,243.2976923076923,248.36153846153846,253.42538461538462,258.48923076923074,263.5530769230769,268.61692307692306,273.6807692307692,278.7446153846154,283.80846153846153,288.8723076923077,293.93615384615384,{"y":299,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,233.17,234.73153846153846,236.2930769230769,237.85461538461539,239.41615384615383,240.9776923076923,242.53923076923076,244.10076923076923,245.66230769230768,247.22384615384615,248.7853846153846,250.34692307692308,251.90846153846155,{"y":253.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,233.17,232.3876923076923,231.6053846153846,230.8230769230769,230.04076923076923,229.25846153846152,228.47615384615384,227.69384615384615,226.91153846153847,226.12923076923076,225.34692307692308,224.5646153846154,223.78230769230768,{"y":223,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":198.885,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":200.716,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":189.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":181.851,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.661,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.692,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":206.949,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":239.021,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":216.973,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.002,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.323,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.03,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.17,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$299.00Average Price Target$253.47Lowest Price Target$223.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on GB:0QCV
Evan Seigerman
BMO Capital
BMO Capital
$258
Buy
21.89%
Upside
Reiterated
03/27/26
AbbVie: Immunology Strength, Strategic Acquisitions, and Patent Headwind Execution Support Buy Rating
Piper Sandler Analyst forecast on GB:0QCV
David Amsellem
Piper Sandler
Piper Sandler
$299
Buy
41.26%
Upside
Reiterated
03/26/26
Piper Sandler Keeps Their Buy Rating on AbbVie (ABBV)
Wells Fargo Analyst forecast on GB:0QCV
Mohit Bansal
Wells Fargo
Wells Fargo
$260
Buy
22.83%
Upside
Assigned
03/12/26
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Relay Therapeutics (RLAY)
Berenberg Bank Analyst forecast on GB:0QCV
Luisa Hector
Berenberg Bank
Berenberg Bank
$275
Buy
29.92%
Upside
Reiterated
03/12/26
AbbVie (ABBV) Receives a Buy from Berenberg Bank
Citi Analyst forecast on GB:0QCV
Geoff Meacham
Citi
Citi
$230
Hold
8.66%
Upside
Reiterated
03/10/26
Neutral Hold on AbbVie as Early Cardiometabolic Pipeline Shows Promise but Trails Leading Competitors
Scotiabank Analyst forecast on GB:0QCV
Louise Chen
Scotiabank
Scotiabank
$280
Buy
32.28%
Upside
Reiterated
03/10/26
Scotiabank Reaffirms Their Buy Rating on AbbVie (ABBV)
William Blair Analyst forecast on GB:0QCV
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
03/09/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Delcath Systems (NASDAQ: DCTH)
J.P. Morgan Analyst forecast on GB:0QCV
Chris Schott
J.P. Morgan
J.P. Morgan
$260
Buy
22.83%
Upside
Reiterated
03/05/26
J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
Morgan Stanley Analyst forecast on GB:0QCV
Terence Flynn
Morgan Stanley
Morgan Stanley
$269→$270
Buy
27.56%
Upside
Reiterated
03/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
DBS Analyst forecast on GB:0QCV
Nico Chen
DBS
DBS
$230
Hold
8.66%
Upside
Reiterated
02/25/26
DBS Sticks to Their Hold Rating for AbbVie (ABBV)
RBC Capital Analyst forecast on GB:0QCV
Trung Huynh
RBC Capital
RBC Capital
$260
Buy
22.83%
Upside
Initiated
02/24/26
AbbVie initiated with an Outperform at RBC CapitalAbbVie initiated with an Outperform at RBC Capital
Barclays Analyst forecast on GB:0QCV
Emily Field
Barclays
Barclays
$275
Buy
29.92%
Upside
Initiated
02/19/26
AbbVie initiated with an Overweight at BarclaysAbbVie initiated with an Overweight at Barclays
Bernstein Analyst forecast on GB:0QCV
Courtney Breen
Bernstein
Bernstein
$225
Hold
6.30%
Upside
Reiterated
02/06/26
Balanced Risk-Reward and Fading Upside Visibility Keep AbbVie at Market-Perform (Hold) with $225 Target
Guggenheim Analyst forecast on GB:0QCV
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$242
Buy
14.33%
Upside
Reiterated
02/05/26
AbbVie (ABBV) Receives a Buy from Guggenheim
Bank of America Securities Analyst forecast on GB:0QCV
Jason Gerberry
Bank of America Securities
Bank of America Securities
$233→$226
Hold
6.77%
Upside
Reiterated
02/05/26
Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on GB:0QCV
Evan Seigerman
BMO Capital
BMO Capital
$258
Buy
21.89%
Upside
Reiterated
03/27/26
AbbVie: Immunology Strength, Strategic Acquisitions, and Patent Headwind Execution Support Buy Rating
Piper Sandler Analyst forecast on GB:0QCV
David Amsellem
Piper Sandler
Piper Sandler
$299
Buy
41.26%
Upside
Reiterated
03/26/26
Piper Sandler Keeps Their Buy Rating on AbbVie (ABBV)
Wells Fargo Analyst forecast on GB:0QCV
Mohit Bansal
Wells Fargo
Wells Fargo
$260
Buy
22.83%
Upside
Assigned
03/12/26
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Relay Therapeutics (RLAY)
Berenberg Bank Analyst forecast on GB:0QCV
Luisa Hector
Berenberg Bank
Berenberg Bank
$275
Buy
29.92%
Upside
Reiterated
03/12/26
AbbVie (ABBV) Receives a Buy from Berenberg Bank
Citi Analyst forecast on GB:0QCV
Geoff Meacham
Citi
Citi
$230
Hold
8.66%
Upside
Reiterated
03/10/26
Neutral Hold on AbbVie as Early Cardiometabolic Pipeline Shows Promise but Trails Leading Competitors
Scotiabank Analyst forecast on GB:0QCV
Louise Chen
Scotiabank
Scotiabank
$280
Buy
32.28%
Upside
Reiterated
03/10/26
Scotiabank Reaffirms Their Buy Rating on AbbVie (ABBV)
William Blair Analyst forecast on GB:0QCV
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
03/09/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Delcath Systems (NASDAQ: DCTH)
J.P. Morgan Analyst forecast on GB:0QCV
Chris Schott
J.P. Morgan
J.P. Morgan
$260
Buy
22.83%
Upside
Reiterated
03/05/26
J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
Morgan Stanley Analyst forecast on GB:0QCV
Terence Flynn
Morgan Stanley
Morgan Stanley
$269→$270
Buy
27.56%
Upside
Reiterated
03/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
DBS Analyst forecast on GB:0QCV
Nico Chen
DBS
DBS
$230
Hold
8.66%
Upside
Reiterated
02/25/26
DBS Sticks to Their Hold Rating for AbbVie (ABBV)
RBC Capital Analyst forecast on GB:0QCV
Trung Huynh
RBC Capital
RBC Capital
$260
Buy
22.83%
Upside
Initiated
02/24/26
AbbVie initiated with an Outperform at RBC CapitalAbbVie initiated with an Outperform at RBC Capital
Barclays Analyst forecast on GB:0QCV
Emily Field
Barclays
Barclays
$275
Buy
29.92%
Upside
Initiated
02/19/26
AbbVie initiated with an Overweight at BarclaysAbbVie initiated with an Overweight at Barclays
Bernstein Analyst forecast on GB:0QCV
Courtney Breen
Bernstein
Bernstein
$225
Hold
6.30%
Upside
Reiterated
02/06/26
Balanced Risk-Reward and Fading Upside Visibility Keep AbbVie at Market-Perform (Hold) with $225 Target
Guggenheim Analyst forecast on GB:0QCV
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$242
Buy
14.33%
Upside
Reiterated
02/05/26
AbbVie (ABBV) Receives a Buy from Guggenheim
Bank of America Securities Analyst forecast on GB:0QCV
Jason Gerberry
Bank of America Securities
Bank of America Securities
$233→$226
Hold
6.77%
Upside
Reiterated
02/05/26
Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

3 Months
xxx
Success Rate
17/23 ratings generated profit
74%
Average Return
+6.44%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 73.91% of your transactions generating a profit, with an average return of +6.44% per trade.
1 Year
Evan SeigermanBMO Capital
Success Rate
19/20 ratings generated profit
95%
Average Return
+17.14%
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +17.14% per trade.
2 Years
xxx
Success Rate
28/29 ratings generated profit
97%
Average Return
+31.94%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 96.55% of your transactions generating a profit, with an average return of +31.94% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QCV Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
0
0
0
0
0
Buy
37
32
28
28
30
Hold
17
16
15
14
13
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
54
48
43
42
43
In the current month, 0QCV has received 30 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. 0QCV average Analyst price target in the past 3 months is 253.47.
Each month's total comprises the sum of three months' worth of ratings.

0QCV Financial Forecast

0QCV Earnings Forecast

Next quarter’s earnings estimate for 0QCV is $3.02 with a range of $2.97 to $3.17. The previous quarter’s EPS was $2.71. 0QCV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 0QCV has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0QCV is $3.02 with a range of $2.97 to $3.17. The previous quarter’s EPS was $2.71. 0QCV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 0QCV has Performed in-line its overall industry.

0QCV Sales Forecast

Next quarter’s sales forecast for 0QCV is $14.72B with a range of $14.56B to $14.85B. The previous quarter’s sales results were $16.62B. 0QCV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 0QCV has Performed in-line its overall industry.
Next quarter’s sales forecast for 0QCV is $14.72B with a range of $14.56B to $14.85B. The previous quarter’s sales results were $16.62B. 0QCV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 0QCV has Performed in-line its overall industry.

0QCV Stock Forecast FAQ

What is GB:0QCV’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbvie’s 12-month average price target is 253.47.
    What is GB:0QCV’s upside potential, based on the analysts’ average price target?
    Abbvie has 19.75% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Abbvie a Buy, Sell or Hold?
          Abbvie has a consensus rating of Moderate Buy, which is based on 15 buy ratings, 7 hold ratings and 0 sell ratings.
            What is Abbvie’s share price target?
            The average share price target for Abbvie is 253.47. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $299.00 ,and the lowest forecast is $223.00. The average share price target represents 19.75% Increase from the current price of $211.67.
              What do analysts say about Abbvie?
              Abbvie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of Abbvie?
                To buy shares of GB:0QCV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.